IMIC(SZ:000516) Sou Hu Cai Jing·2025-12-02 01:25Core Viewpoint - The company is addressing investor concerns regarding declining revenue and profits while maintaining operational efficiency through cost management strategies [1] Financial Performance - As of Q3 2025, the company's management expense ratio is 10.99%, showing a year-on-year decrease of 0.54 percentage points and a quarter-on-quarter decrease of 2.13 percentage points [1] - The financial expense ratio stands at 3.43%, with a year-on-year decrease of 0.07 percentage points and a quarter-on-quarter decrease of 0.25 percentage points [1] Cost Management Strategies - The company is focusing on optimizing medical service quality, clinical pathway management, reducing drug consumption, and optimizing cost structure to enhance operational efficiency [1] - Future efforts will continue to emphasize cost control, with expectations for further optimization of financial costs as depreciation and interest expenses decline [1]